The challenge isnt creating more GLP-1its understanding how to activate the cells that produce it and protect the hormone from rapid degradation
The patience pays off in clearer understanding of your individual response
Back Elrick, H., Stimmler, L, Arai, Y (1964) 'Plasma insulin response to oral and intravenous glucose administration', Journal Clinical Endocrinology Metabolism , 24/10, 107682
North Carolina eliminated GLP-1 coverage beginning October 2025 due to a budget stalemate in the legislature, but coverage was reinstated in December 2025, bringing the total number of states covering GLP-1s for obesity to 13 as of January 2026
The $149 introductory rate applies to 1.5mg and 4mg doses for the first four months, with prices increasing as patients move to higher, longterm doses